Compare BioNano Genomics Inc (BNGO) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs iShares MSCI China ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while iShares MSCI China ETF trades at $55.12. The key difference: iShares MSCI China ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MCHI | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $66.99 |
52-Week Low | $1.06 | $50.48 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
MCHI trades at $55.08, down 3.25% today amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. The ETF's valuation appears historically cheap compared to US indices, with recent news highlighting China's strong export performance and institutional buying activity. A dividend of $0.36 is scheduled for June 2026.
MCHI presents a value opportunity with significant discount to historical averages, supported by China's export strength and AI infrastructure investments. Risks include US-China trade tensions and potential regulatory changes. Institutional interest is mixed with recent buying by Empowered Funds offset by selling from Acima Private Wealth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
